ALISE REICIN
CIK 1757533 · Chief Executive Officer · last filed 2026-06-05
ALISE REICIN is a Chief Executive Officer who has filed 27 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing, for SANA, was dated Jun 5, 2026. Across all open-market trades the lifetime net is +$105.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $13.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$13.28M
4
27
$105.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SANA | Director | — | $2.68 | — | $0 | 8 | 2026-06-05 |
| TECX | Chief Executive Officer | 438,577 | $30.28 | $13.28M | $105.5K | 9 | 2026-03-05 |
| Q32 Bio Inc. (FIXX) Delisted | Director | — | $16.82 | — | $0 | 5 | 2023-06-15 |
| CELGENE CORP /DE/ (CELGZ) Delisted | PRES., GLOBAL CLINICAL DEV. | 0 | — | — | $0 | 4 | 2019-11-22 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | SANA | Grant (A) | — | $0 | EDGAR |
| 2026-03-05 | TECX | Grant (A) | +76,500 | $0 | EDGAR |
| 2026-03-05 | TECX | Buy (P) | +2,500 | $52.8K | EDGAR |
| 2026-02-12 | TECX | Buy (P) | +2,500 | $52.8K | EDGAR |
| 2026-02-10 | TECX | Tax (F) | −4,104 | -$95.3K | EDGAR |
| 2026-01-05 | TECX | Exer (M) | +10,966 | $26.1K | EDGAR |
| 2025-09-29 | TECX | Grant (A) | +14,700 | $0 | EDGAR |
| 2025-06-24 | TECX | Tax (F) | −859 | -$17.0K | EDGAR |
| 2025-06-09 | SANA | Grant (A) | — | $0 | EDGAR |
| 2025-02-06 | TECX | Grant (A) | +36,047 | $0 | EDGAR |